COF
48
3
PNW
55
3
AMP
43
2
IRM
33
5
CTAS
36
8
HSIC
42
2
CF
47
5
HRB
40
3
LRCX
56
4
CMI
49
2
DVA
62
5
CSCO
63
5
VTR
44
4
STT
48
4
CTSH
55
3
MMM
35
3
NWL
48
4
DOW
47
4
EXPD
29
2
WBA
41
3
COF
48
3
PNW
55
3
AMP
43
2
IRM
33
5
CTAS
36
8
HSIC
42
2
CF
47
5
HRB
40
3
LRCX
56
4
CMI
49
2
DVA
62
5
CSCO
63
5
VTR
44
4
STT
48
4
CTSH
55
3
MMM
35
3
NWL
48
4
DOW
47
4
EXPD
29
2
WBA
41
3
Financhill
Back

Aclaris Therapeutics 10K Form

Sell
19

ACRS
Aclaris Therapeutics

Last Price:
$2.90
Seasonality Move:
31.13%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ACRS News And Ratings

See the #1 stock for the next 7 days that we like better than ACRS

ACRS Financial Statistics

Sales & Book Value

Annual Sales: $31.2M
Cash Flow: $22M
Price / Cash Flow: 0
Annual Sales: $1.82
Price / Book: 1.5

Profitability

EPS (TTM): -0.52000
Net Income (TTM): $-37M
Gross Margin: $13.2M
Return on Equity: -25.72%
Return on Assets: -19.83%

Aclaris Therapeutics Earnings Forecast

Key Aclaris Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for ACRS is 42.14%.
  • The Selling, General & Administrative Expenses for ACRS have been equal to 99.52% of Gross Profit Margin.
  • The Research & Development expenses have been 314.84% of Revenue.
  • The Net Earning history of ACRS is -283.15% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Aclaris Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ACRS
CUSIP: 00461U
Website: aclaristx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.03
Quick Ratio: 6.81

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ACRS Technical Analysis vs Fundamental Analysis

Sell
19
Aclaris Therapeutics (ACRS) is a Sell

Is Aclaris Therapeutics a Buy or a Sell?